Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients

Launched by UNIVERSIDAD AUSTRAL DE CHILE · Nov 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how effective Meloxicam is for relieving pain after having a third molar, commonly known as a wisdom tooth, removed. The goal is to see if Meloxicam works better than Ibuprofen, which is a common pain reliever used after dental procedures. The study will include adults aged 18 to 65 who have a wisdom tooth that is partially or fully erupted and ready for extraction. However, certain individuals, such as those with infections, specific health conditions, or those who are pregnant or breastfeeding, will not be eligible to participate.

Participants in this study can expect to receive either Meloxicam or Ibuprofen after their tooth extraction and then report on their pain levels. The trial is currently not recruiting participants yet, but it aims to help determine the best pain management option for patients undergoing this common dental procedure. If you or a loved one are considering participating, it’s important to discuss any health concerns with your dentist or doctor to see if you qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Maxillary or mandibular third molar with semi or fully erupted crown.
• Exclusion Criteria:
• • Patients with Systemic pathologies. Presence of third molar localized infection. Completely included third molar crown. Periodontal compromise. Pregnant or breastfeeding women. Patients with hypersensitivity to NSAIDs. Patients with a history of drug abuse. Patients who had taken any drug in the previous 24 hours. Intervention (exodontia) time longer than 45 minutes.